# Frequently Asked Questions > FAQ — GHK-Cu, Ipamorelin & Tesamorelin — Clean Peptides Lab — Direct, cited answers to common questions about GHK-Cu, ipamorelin and tesamorelin — mechanism, evidence, risks and what lab-grade quality claims can and cannot tell a reader. **FAQ** Direct answers to the questions readers most often bring to this desk, cited back to the source. ## What does a GHK-Cu peptide do? GHK-Cu is a copper-binding tripeptide best studied as a topical cosmetic ingredient. It stimulates dermal fibroblasts to make more collagen, elastin and other matrix proteins, and the copper it carries supports enzymes involved in cross-linking and antioxidant activity [6][7]. In reviewed studies, topical GHK-Cu increased procollagen synthesis in about 70% of treated subjects, compared with 50% for vitamin C and 40% for retinoic acid [1][4]. It has no approved indication for injection or systemic use. ## What is GHK-Cu and how does it work? GHK-Cu is glycyl-L-histidyl-L-lysine bound to a copper(II) ion, occurring naturally within human collagen. It works by acting on dermal fibroblasts, keratinocytes and other cell types at extremely low concentrations, shifting gene expression toward tissue-repair, antioxidant and protein-quality-control programs — an effect measured across roughly 31.2% of human genes at a 50%-or-greater change threshold in gene-expression analysis [2]. ## Is GHK-Cu peptide really anti-aging? The controlled human evidence supports specific, measured skin effects — increased procollagen synthesis and, in a related combination formulation, a significant hair-count increase over placebo [1][3][4] — rather than a general "anti-aging" claim. Most of the broader anti-aging narrative around GHK-Cu extrapolates from cell, rodent and gene-database work, much of it from a single research group, beyond what the small human topical trials directly demonstrate [1][4]. This site reports the measured findings and flags where the marketing outruns them. ## What is the difference between GHK and GHK-Cu? GHK is the bare three-amino-acid peptide; GHK-Cu is that same peptide bound to a copper ion. The copper coordination is not incidental — laboratory studies indicate that plain GHK without bound copper does not reproduce key documented effects, such as stimulation of certain matrix-remodeling enzymes, in cell studies. Most of the literature summarized on this hub is specific to the copper-bound complex, and the form used in a given study matters when comparing claims. ## What is ipamorelin? Ipamorelin is a synthetic five-amino-acid peptide that selectively triggers growth hormone release by activating the ghrelin receptor (GHS-R1a) on pituitary cells. Its defining pharmacological feature is that it does this without meaningfully raising cortisol or prolactin, distinguishing it from older secretagogues [11]. It has never been approved as a drug and has one published human efficacy trial, which did not meet its primary endpoint [10]. ## What does ipamorelin do for you? In its founding pharmacology, ipamorelin triggers a discrete pulse of growth hormone release, peaking about 40 minutes after dosing in a small human pharmacokinetic study [11]. Beyond that acute GH pulse, the only controlled human efficacy trial — testing whether it sped recovery after bowel surgery — found no statistically significant benefit over placebo [10]. Reported sleep, recovery and body-composition effects circulating in research communities are anecdotal, not clinical evidence, and are not established by any published human trial. ## What is ipamorelin peptide? Ipamorelin is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from an earlier compound (GHRP-1) by removing a central segment. It is sold as a research chemical and is not FDA-approved for any human use; in 2024 the FDA also removed ipamorelin acetate from the interim list of substances a compounding pharmacy may legally use. ## What are the risks of ipamorelin? The documented risks are mostly mechanistic rather than directly observed in ipamorelin-specific human data: growth-hormone-axis stimulation carries a class-level, theoretical cancer caution tied to IGF-1's role as a growth signal, and a related receptor-class compound produced heart-tissue damage in a 28-day rat study, a class-level signal rather than an ipamorelin-specific finding [9]. No long-term human safety study of ipamorelin exists at any dose, and research-grade material from unregulated suppliers carries no pharmaceutical purity assurance. ## What is tesamorelin? Tesamorelin is a synthetic 44-amino-acid analogue of human growth-hormone-releasing hormone (GHRH), modified to resist rapid enzymatic breakdown. It is the only compound on this hub with an FDA approval — since 2010, to reduce excess abdominal fat in people with HIV-associated lipodystrophy [15]. ## What does tesamorelin do? Tesamorelin stimulates the body's own pulsatile release of growth hormone, which in turn raises IGF-1 and promotes fat breakdown with a preference for visceral fat. A 2026 meta-analysis of five pooled randomized trials found it reduced visceral fat by roughly 27.7 square centimeters and liver fat by about 4.3 percentage points on average, without a significant increase in serious adverse events [13]. ## How does tesamorelin work? It binds the GHRH receptor on pituitary somatotroph cells, activating a signaling cascade that increases growth hormone synthesis and release. The resulting GH drives hepatic IGF-1 production, and GH and IGF-1 together promote lipolysis, preferentially in visceral fat depots [16]. Because it amplifies an existing physiological rhythm rather than supplying growth hormone directly, its metabolic profile differs somewhat from recombinant growth hormone therapy. ## Will tesamorelin help me lose belly fat? Tesamorelin's approval and its strongest trial evidence are specific to visceral-fat reduction in people with HIV-associated lipodystrophy, a defined medical condition [13][15][17]. Trial data in that population show a real, statistically significant visceral-fat reduction, but the effect was not shown to be permanent — a 52-week program found fat reaccumulated once treatment stopped [17]. This site does not make a general fat-loss recommendation outside the population and indication the trials actually studied, and describes no dosing for any use. --- Clean Peptides Lab reads the purity, testing and quality-signal literature on GHK-Cu, ipamorelin and tesamorelin; it runs no assays, holds no certification, and is a reading desk, not a laboratory.